

Kristine Kleivi Sahlberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5880083/publications.pdf>

Version: 2024-02-01

21
papers

946
citations

623574

14
h-index

752573

20
g-index

21
all docs

21
docs citations

21
times ranked

2225
citing authors

#	ARTICLE	IF	CITATIONS
1	True and Missed Interval Cancer in Organized Mammographic Screening: A Retrospective Review Study of Diagnostic and Prior Screening Mammograms. <i>Academic Radiology</i> , 2022, 29, S180-S191.	1.3	19
2	Abstract OT2-19-01: Presurgical treatment with ribociclib and letrozole in patients with locally advanced breast cancer: The NEOLETRIB study. <i>Cancer Research</i> , 2022, 82, OT2-19-01-OT2-19-01.	0.4	0
3	NRF2 drives an oxidative stress response predictive of breast cancer. <i>Free Radical Biology and Medicine</i> , 2022, 184, 170-184.	1.3	8
4	miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy. <i>Breast Cancer: Targets and Therapy</i> , 2022, Volume 14, 25-39.	1.0	3
5	Radiological review of prior screening mammograms of screen-detected breast cancer. <i>European Radiology</i> , 2021, 31, 2568-2579.	2.3	18
6	miRNA normalization enables joint analysis of several datasets to increase sensitivity and to reveal novel miRNAs differentially expressed in breast cancer. <i>PLoS Computational Biology</i> , 2021, 17, e1008608.	1.5	1
7	MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro. <i>Scientific Reports</i> , 2021, 11, 10893.	1.6	18
8	Interval and Consecutive Round Breast Cancer after Digital Breast Tomosynthesis and Synthetic 2D Mammography versus Standard 2D Digital Mammography in BreastScreen Norway. <i>Radiology</i> , 2020, 294, 256-264.	3.6	55
9	Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer. <i>Oncology</i> , 2020, 9, 1824644.	2.1	17
10	miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer. <i>Molecular Oncology</i> , 2019, 13, 2278-2296.	2.1	30
11	An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment. <i>Nature Communications</i> , 2019, 10, 5499.	5.8	132
12	DNA methylation at enhancers identifies distinct breast cancer lineages. <i>Nature Communications</i> , 2017, 8, 1379.	5.8	103
13	Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. <i>Breast Cancer: Targets and Therapy</i> , 2017, Volume 9, 185-198.	1.0	23
14	A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7. <i>Thrombosis Research</i> , 2017, 157, 111-116.	0.8	21
15	Determinants of acquired activated protein C resistance and D-dimer in breast cancer. <i>Thrombosis Research</i> , 2016, 145, 78-83.	0.8	8
16	Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF. <i>Breast Cancer Research</i> , 2015, 17, 44.	2.2	24
17	A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 1207-1214.	3.2	191
18	Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer. <i>Genome Medicine</i> , 2015, 7, 21.	3.6	34

#	ARTICLE	IF	CITATIONS
19	High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. <i>Molecular Oncology</i> , 2014, 8, 93-104.	2.1	146
20	The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells – A data description. <i>Genomics Data</i> , 2014, 2, 249-253.	1.3	15
21	The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. <i>Molecular Oncology</i> , 2013, 7, 392-401.	2.1	80